A citation-based method for searching scientific literature

H J Lambers Heerspink, D de Zeeuw, L Wie, B Leslie, J List. Diabetes Obes Metab 2013
Times Cited: 472



Hiddo J L Heerspink, Paul Perco, Skander Mulder, Johannes Leierer, Michael K Hansen, Andreas Heinzel, Gert Mayer. Diabetologia 2019
Times Cited: 139




List of shared articles



Times cited

Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease.
Hongyan Liu, Vikas S Sridhar, Jacinthe Boulet, Atit Dharia, Abid Khan, Patrick R Lawler, David Z I Cherney. Metabolism 2022
3



Interaction between sodium-glucose co-transporter 2 and the sympathetic nervous system.
Omar Azzam, Vance B Matthews, Markus P Schlaich. Curr Opin Nephrol Hypertens 2022
1

Prediction of the Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Based on Short-Term Changes in Multiple Risk Markers.
Sok Cin Tye, Sieta T de Vries, Christoph Wanner, Petra Denig, Hiddo J L Heerspink. Front Pharmacol 2022
2

Beneficial cardiovascular and remodeling effects of SGLT 2 inhibitors.
Steven G Chrysant, George S Chrysant. Expert Rev Cardiovasc Ther 2022
0

An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors.
Teresa Salvatore, Raffaele Galiero, Alfredo Caturano, Luca Rinaldi, Anna Di Martino, Gaetana Albanese, Jessica Di Salvo, Raffaella Epifani, Raffaele Marfella, Giovanni Docimo,[...]. Int J Mol Sci 2022
0

Sodium-Glucose Cotransporter-2 Inhibitors Improve Heart Failure with Reduced Ejection Fraction Outcomes by Reducing Edema and Congestion.
Michelle Hernandez, Ryan D Sullivan, Mariana E McCune, Guy L Reed, Inna P Gladysheva. Diagnostics (Basel) 2022
1

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
Katherine R Tuttle, Frank C Brosius, Matthew A Cavender, Paola Fioretto, Kevin J Fowler, Hiddo J L Heerspink, Tom Manley, Darren K McGuire, Mark E Molitch, Amy K Mottl,[...]. Diabetes 2021
17

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
Katherine R Tuttle, Frank C Brosius, Matthew A Cavender, Paola Fioretto, Kevin J Fowler, Hiddo J L Heerspink, Tom Manley, Darren K McGuire, Mark E Molitch, Amy K Mottl,[...]. Am J Kidney Dis 2021
37



Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics.
Zhenghong Liu, Xiaoxuan Ma, Iqra Ilyas, Xueying Zheng, Sihui Luo, Peter J Little, Danielle Kamato, Amirhossein Sahebkar, Weiming Wu, Jianping Weng,[...]. Theranostics 2021
17